|
Und noch ein STRONG BUY: Auszüge aus den kostenpflichtigen YORKTON-Report: Recommendation: STRONG BUY 12 to 18-Month Target Price: $18.00 New Agreements for its Genomic Platform. Licensing its Gene-Based Assays, Strong Subunit Vaccine Portfolio Progessing ... We believe that ID Biomedical’s proprietary CPT offers the optimal balance of speed, accuracy, ease of use and cost, compared to other amplification and detection techniques. ... The many benefits that CPT has the potential to offer current genomic analysis prompted Applied Biosystems to sign a US$5 million non-exclusive licensing agreement for the use of CPT. Applied Biosystems will apply CPT to its own platforms in the areas of genomics, high throughput screening and the development of assays to detect nucleic acids. Applied Biosystems is focused on the development of fully automated instruments for genomics analysis and it was its ABI Prism® 3700 DNA Analysers which allowed for the sequencing of the human genome by Celera (CRA, NYSE) and other research groups. Applied Biosystems is now developing a new platform instrument for genomic analysis called Sequence Detection Systems (SDS). This illustrates the move from sequencing to detection that the industry is currently making. ... As ID Biomedical enters partnerships and licensing agreements with other biotechnology companies, we believe CPT will be widely used in a variety of genomic analyses. ... We expect clinical testing to be completed by the end of the year with the Velogene™ Genomic Identification Assay for VRE to be launched early in 2001. ... ID Biomedical’s strategy is to take its vaccine products into late stage clinical development prior to licensing them to multinational vaccine manufacturers/distributors. This should allow ID Biomedical to significantly increase revenues form its vaccine products once they reach the market. Typically, if companies license out a product early in the development cycle (i.e., at Phase I), a royalty of about 10% can be expected. If the product is developed through Phase III clinical trials, a revenue sharing arrangement with royalties up to 50% is possible. ... The company also intends to expand the number of vaccines in its development pipeline through the licensing or acquisition of proprietary vaccine candidates that have shown promising potential in early clinical development or in pre-clinical development. ... ID Biomedical has an exceptional management team which we believe provides the optimal mix of business and research experience and insight. gruss elbono |
|
| aus der Diskussion: | ----- ID Biomedical----- |
| Autor (Datum des Eintrages): | elbono (17.10.00 11:04:45) |
| Beitrag: | 6 von 13 (ID:2096024) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |